Vandana Singh

Lonza unveils its "One Lonza" strategy, highlighting a new structure to streamline operations, strengthen CDMO leadership, and project 20% CER sales growth in 2025.

Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and tolerable safety for advanced breast cancer therapy.

Novavax sells Czech manufacturing facility to Novo Nordisk for $200 million, aiming to cut costs by $80 million annually and support its growth strategy.

Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes.

Adial Pharmaceuticals expands its IP with a U.S. patent for targeted AUD treatment using AD04, supporting its personalized medicine strategy.

Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for faster, accurate results.

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties.

Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

The FDA is investigating reports of life-threatening blood cancers linked to Skysona, a gene therapy for CALD. Providers are urged to consider safer alternatives and monitor patients for malignancies.